Treatment of patients with high-grade non-Hodgkin's lymphoma aged over 70 years with an all-oral regimen combining idarubicin, etoposide and alkylators

Critical Reviews in Oncology/Hematology

Volumn 35, Issue 2, 2000, Pages 95-100

  Morra, Enrica ^a   Gargantini, Livio ^a   Nosari, Annamaria ^a   Barbarano, Luciana ^a   Pungolino, Ester ^a   Santoleri, Luca ^a   Bernuzzi, Patrizia ^a  

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; CHLORAMBUCIL; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; PREDNIMUSTINE; PREDNISONE;

AGE; AGED; ALOPECIA; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER STAGING; CLINICAL ARTICLE; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HOSPITALIZATION; HUMAN; INFECTION; LEUKOPENIA; MALE; NONHODGKIN LYMPHOMA; OUTPATIENT; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGE FACTORS; AGED; AGED, 80 AND OVER; AGRANULOCYTOSIS; ALKYLATING AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; DRUG EVALUATION; ETOPOSIDE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IDARUBICIN; LYMPHOMA, NON-HODGKIN; MALE; PREDNIMUSTINE; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0033902945     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(00)00065-2     Document Type: Article

References (22)

1. Shipp M., Harrington D., Anderson J. et al. A predictive model for aggressive non-Hodgkin's lymphoma. New Engl. J. Med. 329:1993;987-994.
2. D'Amore F., Brinker H., Christensen B.E. et al. Non-Hodgkin's lymphoma in the elderly. A study of 602 patients aged 70 or older from a Danish population-based registry. Ann. Oncol. 3:1992;379-386.
3. The non-Hodgkin's Lymphoma Classification Project. Effect of age on the characteristics and clinical behaviour of non-Hodgkin's lymphoma patients, Ann Oncol 1997;8:973-78.
4. Quaglino D., Di Leonardo G., Furia N. et al. Therapeutic management of hematological malignancies in elderly patients. Biological and clinical considerations. Part II: non-Hodgkin's lymphomas and Hodgkin's disease. Aging. 9:1997;310-319.
5. Sonnenveld P., Michiels J.J. Full dose chemotherapy in elderly patients with non-Hodgkin's lymphoma. A feasibility study using a mitoxantrone-containing regimen. Br. J. Cancer. 62:1990;105-110.
6. Errante D., Sorio R., Zagonel V. et al. A phase II study of oral idarubicin (4-demethoxidaunorubicin) in previously untreated elderly patients with non-Hodgkin's lymphoma. Am. J. Clin. Oncol. Cancer Clin. Trials. 14:1991;243-245.
7. Salvagno L., Contu A., Bianco A. A combination of mitoxantrone, etoposide and prednisone in elderly patients with non-Hodgkin's lymphoma. Ann. Oncol. 3:1992;833-837.
8. Zinzani P.L., Pavone E., Storti S. et al. Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin's lymphoma. Blood. 89:1997;3974-3979.
9. Tirelli U., Errante D., Van Glabbeke M. et al. CHOP is the standard regimen in patients ≥70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group. J. Clin. Oncol. 16:1998;27-34.
10. Gomez H., Mas L., Casanova L. et al. Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: identification of two age subgroups with differing hematologic toxicity. J. Clin. Oncol. 16:1998;2352-2358.
11. Christoffersen P.S., Rasmussen K.K., Hermansen K. Cardiovascular effects of doxorubicin (adriamycin) and 4-demethoxydaunorubicin (idarubicin) in the conscious rat. Pharmacol. Toxicol. 62:1988;54-56.
12. Robert J., Rigal-Huguet F., Huet S. et al. Pharmacokinetics of idarubicin after oral administration in elderly leukemic patients. Leukemia. 4:1990;227-229.
13. Case D.C., Hayes D.M., Gerber M.C. Phase II study of oral idarubicin in favourable histology non-Hodgkin's lymphoma. Cancer Res. 50:1990;6833-6835.
14. Proctor S.J., Taylor P.R.A. The use or oral idarubicin, chlorambucil and dexamethasone in low-grade non-Hodgkin's lymphoma. Res. Clin. Forum. 18(3):1996;29-34.
15. Mileti A, Pavone V, Guarini A et al. Association of idarubicin and prednimustine. Preliminary study of 25 patients with non-Hodgkin's lymphoma in the advanced stage [in Italian]. Haematologica. 79(Suppl 1):1994;130-132.
16. Niitsu N., Nakayama M., Umeda M. Effectiveness of prolonged oral therapy with low-dose etoposide in patients aged 85 years and over with non-Hodgkin's lymphoma. Nippon Ronen Igakkai Zasshi. 34:1997;263-266.
17. Ruutu T., Almqvist A., Hallman H. et al. Oral induction and consolidation of acute myeloid leukemia with etoposide, 6-thioguanine, and idarubicin (ETI) in elderly patients: a randomized comparison with 5-day TAD. Finnish Leukemia Group. Leukemia. 8:1994;11-15.
18. Jackson G.H., Taylor R.P., Iqbal A. et al. The use of an all oral chemotherapy (idarubicin and etoposide) in the treatment of acute myeloid leukemia in the elderly: a report of toxicity and efficacy. Leukemia. 11:1997;1193-1196.
19. Stansfeld A., Diebold J., Kapauci Y. et al. Updated Kiel classification for lymphoma. Lancet. 1:1988;292-293.
20. Pannuti F., Camaggi C.M., Strocchi E. et al. Low dose oral administration of 4-demethoxydaunorubicin (idarubicin) in advanced cancer patients. Cancer Chemother. Pharmacol. 16:1986;295-299.
21. Toffoli G., Sorio R., Aita P. et al. Pharmacology of chronic oral daily administration of idarubicin. Haematologica. 82(5):1997;1-3.
22. Zinzani P.L., Storti S., Zaccaria A. et al. Elderly aggressive-histology non-Hodgkin's lymphoma: first-line VNCOP-B regimen experience on 350 patients. Blood. 94:1999;33-38.